Detecting Deception in Our Research Participants: Are Your Participants Who You Think They Are?
Authors:
- 29 December 2017
- journal article
- review article
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 42 (2) , 230-237
Abstract
There is increasing awareness of the potential negative impacts of participant deception on research, including possibly undermining reliability and reproducibility of study findings. These deceptive individuals set their personal interests above the rules of study participation, thereby jeopardizing data quality as well as placing themselves and others at risk. The costs of participant deception are numerous. Overall, it reduces statistical power and may even result in false conclusions about efficacy and safety. To date, most studies have not utilized sufficient methods to detect rule‐breaking subjects. The purpose of this article is to bring to the attention of alcohol and other drug researchers issues involving deceptive participants. The review will suggest alcohol‐specific as well as more general strategies to identify and thereby minimize enrollment of these deceptive participants. Specifically, we will identify strategies that are employed in different phases of human alcohol research and advance approaches that may be helpful to the field in reducing these contaminants. As a field, we need to be more proactive in identifying the deceptive participant even at the cost of more burdensome study enrollment. In light of the systemic nature and multipronged damage that this emerging pattern of deception inflicts on clinical research, it is imperative that we each assume greater responsibility for our role in mitigating this source of research contamination.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (U01AA020890)
- National Institute on Drug Abuse (R01DA026823, U24AA020801, R01DA042094, R01AA023483)
This publication has 15 references indexed in Scilit:
- Strategies to exclude subjects who conceal and fabricate information when enrolling in clinical trialsContemporary Clinical Trials Communications, 2017
- Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With SchizophreniaJMIR mHealth and uHealth, 2017
- Medication Nonadherence, “Professional Subjects,” and Apparent Placebo RespondersJournal of Clinical Psychopharmacology, 2015
- Deception by Research ParticipantsNew England Journal of Medicine, 2015
- Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over TimePLOS ONE, 2015
- Concealment and fabrication by experienced research subjectsClinical Trials, 2013
- Subversive Subjects: Rule-Breaking and Deception in Clinical TrialsJournal of Law, Medicine & Ethics, 2013
- Assessing the adequacy of postexperimental inquiries in deception research and the factors that promote participant honestyBehavior Research Methods, 2011
- Alcohol Biomarkers in Applied Settings: Recent Advances and Future Research OpportunitiesAlcohol, Clinical and Experimental Research, 2010
- Medical histories may be unreliable in screening volunteers for clinical trialsClinical Pharmacology & Therapeutics, 1996